Investing in biotechnology requires a balance between groundbreaking scientific innovation and the realities of clinical development.
Choosing between CRISPR Therapeutics (NASDAQ:CRSP) and Viking Therapeutics (NASDAQ:VKTX) involves comparing established gene-editing leadership against massive growth potential in metabolic medicine
CRISPR Therapeutics is a leader in gene editing, recently achieving its first product approval for rare blood disorders. Viking Therapeutics focuses on metabolic and endocrine disorders, targeting the booming market for weight-loss treatments. While both companies operate in high-growth areas, their financial stages and clinical risks offer distinct paths for everyday investors.
The case for CRISPR Therapeutics CRISPR Therapeutics focuses on developing gene-based medicines using its proprietary CRISPR/Cas9 platform. The company develops gene-based medicines, a transformative part of healthcare stocks. It currently relies on a strategic partnership with Vertex Pharmaceuticals (NASDAQ:VRTX) for the commercialization of CASGEVY, a treatment for sickle cell disease.